FDA Fast-Tracks Immunotherapy That Let Most Rectal Cancer Patients Skip Surgery
The FDA has given accelerated approval to GSK’s Jemperli (dostarlimab) as the first immunotherapy for MSI-H/dMMR locally advanced rectal cancer, after a trial in which most patients avoided surgery, radiation and chemotherapy.